Watch this dynamic webinar for valuable insights into characterizing the stability of an engineered adeno-associated virus (AAV) serotype under moderate thermal stress and physiological solution ...

PHILADELPHIA--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in AAV gene therapy, has announced new research published today in Science Translational Medicine, ...

A new study offers the first atomic-scale view of an interaction between the HIV capsid - the protein coat that shepherds HIV into the nucleus of human cells - and a host protein known as cyclophilin ...

The FDA granted priority review, with a decision expected by June 19, 2025. LEN represents a novel class of HIV therapies by targeting the viral capsid, a multifunctional protein essential for HIV ...

Coarse-grained simulations of HK97 genome packaging. A motor protein pushes DNA through a portal into the capsid, where the DNA coils into switchback loops. DNA is colored in order of entry into the ...

RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced it has entered into a license agreement with Genentech, a member of the Roche ...

Ancient viral fossils buried in our DNA are offering fresh clues about how today’s respiratory pathogens infect and spread. By tracing the shared architecture between long-extinct retroviruses and ...

High-quality HIV antigens for cutting-edge solutions. On February 18, 2025, Gilead Sciences (CA, US) announced a significant milestone: the US FDA accepted their New Drug Applications (NDAs) for ...